Stockholm3 independently validated at the world-renowned Martini Klinik

Stockholm3 has been independently, externally validated at the Martini Klinik, the world-renowned prostate cancer center in Hamburg, Germany. The Martini validation study demonstrated results consistent with previous Stockholm3 studies, achieving a 52 percent reduction of unnecessary biopsies.

“The results of our validation study of Stockholm3 further support its accuracy and generalizability in early detection of significant prostate cancer. The study has provided further support for the Martini Klinik in implementing Stockholm3 in clinical practice,” says Professor Derya Tilki, MD and Principal Investigator of the study.

The Martini Klinik evaluated the performance of both Stockholm3 and the Rotterdam prostate cancer risk calculator (SWOP) in men that met German standards of care to undergo prostate biopsy based on elevated PSA or abnormal rectal exam. In total, 405 men were included in the evaluation. Stockholm3 had a better area under the curve compared to both the SWOP risk calculator and PSA. Findings show that by using Stockholm3, the number of men that underwent benign or Grade Group 1 prostate biopsies could be reduced by 52 percent, while, at the same time, detecting 92% of Grade Group ≥2 prostate cancers compared to using PSA ≥3 ng/ml [1]

“The external and independent validation of Stockholm3 by the Martini Klinik further supports the implementation of Stockholm3 as standard of care in prostate cancer diagnostics. This and other studies show that the number of unnecessary biopsies can be reduced and that the number of aggressive cases detected at an early stage can be increased, when the cancer is still possible to treat and cure,” says Martin Steinberg, Executive Chairman of A3P Biomedical.

1. Tilki, D., Rejek, N., Nohe, F., Haese, A., Graefen, M., & Thederan, I. (2024). External Validation of Stockholm3 in a Retrospective German Clinical Cohort. European urology focus, S2405-4569(24)00129-9. Advance online publication. https://doi.org/10.1016/j.euf.2024.07.009

For additional information, please contact:

Cecilia Edström, acting CFO
Telephone: +46 72 226 23 28
Email: cecilia.edstrom@a3p.com

About A3P Biomedical

A3P Biomedical is a company that specializes in advanced prostate cancer diagnostics. A3P’s main product, Stockholm3, is a clinically and commercially validated blood test for early detection and risk stratification of aggressive prostate cancer. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit www.a3p.com

About Stockholm3

Stockholm3 is a blood-based test, that runs a combination of protein biomarkers, genetic biomarkers and clinical information through an algorithm to find the probability of clinically significant cancer at biopsy.

Stockholm3 has been evaluated in clinical studies including more than 90,000 men. It is extensively tested in large population-based screening trials, as well as in real world clinical utility studies in primary care, as a reflex test to PSA at values 1.5-20 ng/ml. Benefits include the ability to reduce unnecessary MRIs, benign and Grade Group 1 prostate biopsies for men with elevated PSA, while simultaneously improving detection of clinically significant cancers in men with low or normal PSA values. Using Stockholm3 leads to a more accurate risk assessment than the current PSA standard. Stockholm3 detects 40-90% more men with aggressive prostate cancer and, at the same time, reduces over-detection by 40-50% compared to PSA.

Multiple Stockholm3 studies have been published in high-impact journals such as The Lancet Oncology, Journal of Clinical Oncology, and European Urology. The studies address both the specificity and sensitivity of Stockholm3 in multi-ethnic populations as well as health-economic benefits of implementing it in clinical care. For more information about our clinical studies please visit www.a3p.com

About prostate cancer

Prostate cancer is the most common cancer in men. In 2020, the global incidence of new prostate cancer cases was 1.4 million, and prostate cancer specific mortality 370,000. Global prostate cancer incidence and mortality is expected to rise by 100% and 85% respectively by 2040, driven by an ageing population.

Links